{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-010935","form_type":"8-K","ticker":"DRIO","cik":"0001533998","company_name":"DarioHealth Corp.","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.433748+00:00","generated_at":"2026-06-20T00:02:47.629658+00:00","sec_items":["2.02","2.04","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"DarioHealth Reports Preliminary FY2022 Revenue of $27.5M and Begins Loan Repayment","bullets":["Preliminary full-year 2022 total revenue expected $27.5M, up from $20.5M in 2021.","B2B channel grew to about 60% of revenue in 2022 versus 4% in 2021.","Operating loss reduced by more than 50% compared to Q4 2021.","Credit agreement with OrbiMed triggers monthly repayments of up to $518,500 starting January 2023.","Cash and equivalents at end of 2022: $49.3 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-010935","json":"https://secwatch.observer/filing/0001104659-23-010935.json","markdown":"https://secwatch.observer/filing/0001104659-23-010935.md","text":"https://secwatch.observer/filing/0001104659-23-010935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/0001104659-23-010935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/tm235559d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:02:47.629658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7fe161b8b9a51604679ab0b6ea4f4c3581c665bc","claim":"DarioHealth Corp. faced acceleration on credit facility of $25 million with OrbiMed Royalty and Credit Opportunities III, LP maturing June 9, 2027.","evidence_excerpt":"the Company started repayment of the outstanding principal amount of the initial tranche of $25 million issued as part of the Loan Facility, together with a repayment premium and other fees in monthly installments of up to $518,500 beginning as of January 31, 2023, and continuing through the maturity date, or June 9, 2027.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/0001104659-23-010935-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$25 million"},{"label":"Counterparty","value":"OrbiMed Royalty and Credit Opportunities III, LP"},{"label":"Maturity","value":"June 9, 2027"},{"label":"Event","value":"acceleration"}],"fact_type":"debt_financing"},{"claim_id":"8810fcb018392af475ef0aa803f912f36cf6eb53","claim":"DarioHealth Corp. reported the fiscal year ended December 31, 2022 results: revenue approximately $27.5 million.","evidence_excerpt":"DarioHealth Corp. (Nasdaq: DRIO) (\"Dario\" or the \"Company\"), a leader in the global digital therapeutics (DTx) market, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/0001104659-23-010935-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"approximately $27.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"aa9f531ef7460a881d4d145381690f837b2b1a85","claim":"DarioHealth Corp. reported the fourth quarter ended December 31, 2022 results: revenue approximately $6.7 million.","evidence_excerpt":"DarioHealth Corp. (Nasdaq: DRIO) (\"Dario\" or the \"Company\"), a leader in the global digital therapeutics (DTx) market, today announced preliminary unaudited revenue results for the fourth quarter and full year 2022 of approximately $6.7 million and approximately $27.5 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533998/000110465923010935/0001104659-23-010935-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"approximately $6.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}